SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-001365
Filing Date
2022-01-14
Accepted
2022-01-14 16:32:11
Documents
12
Period of Report
2022-01-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K trvi-8k_20220110.htm   iXBRL 8-K 40126
  Complete submission text file 0001564590-22-001365.txt   173399

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA trvi-20220110.xsd EX-101.SCH 5729
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20220110_lab.xml EX-101.LAB 20173
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20220110_pre.xml EX-101.PRE 12061
6 EXTRACTED XBRL INSTANCE DOCUMENT trvi-8k_20220110_htm.xml XML 3687
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 22532227
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences